journal
MENU ▼
Read by QxMD icon Read
search

Diabetes Technology & Therapeutics

journal
https://www.readbyqxmd.com/read/27922760/nervecheck-for-the-detection-of-sensory-loss-and-neuropathic-pain-in-diabetes
#1
Georgios Ponirakis, Maria N Odriozola, Samantha Odriozola, Ioannis N Petropoulos, Shazli Azmi, Maryam Ferdousi, Hassan Fadavi, Uazman Alam, Andrew Marshall, Maria Jeziorska, Anthony Miro, Ahmad Kheyami, Mitra Tavakoli, Ahmed Al-Ahmar, Maria B Odriozola, Ariel Odriozola, Rayaz A Malik
BACKGROUND: Accurate and economic detection of nerve damage in diabetes is key to more widespread diagnosis of patients with diabetic peripheral neuropathy (DPN) and painful diabetic neuropathy. This study examined the diagnostic performance of NerveCheck, an inexpensive ($500) quantitative sensory testing (QST) device. METHODS: One hundred forty-four subjects (74 with and 70 without diabetes) underwent assessment with NerveCheck, neuropathy disability score (NDS), nerve conduction studies (NCS), intraepidermal and corneal nerve fiber density (IENFD and CNFD), and McGill questionnaire for neuropathic pain...
December 6, 2016: Diabetes Technology & Therapeutics
https://www.readbyqxmd.com/read/27918671/dpp-4-inhibitor-treatment-in-chinese-type-2-diabetes-patients-a-meta-analysis
#2
Xiaoling Cai, Xueying Gao, Wenjia Yang, Yifei Chen, Lingli Zhou, Simin Zhang, Xueyao Han, Linong Ji
BACKGROUND: The aim of this meta-analysis was to assess the comprehensive clinical efficacy of dipeptidyl peptidase-IV (DPP-4) inhibitors in Chinese type 2 diabetes patients and to evaluate whether there is a different response to treatment with different kinds of DPP-4 inhibitors in those patients. METHODS: Databases were systematically searched, and qualifying clinical studies of Chinese type 2 diabetes patients were included. RESULTS: A total of 30 studies were included...
December 5, 2016: Diabetes Technology & Therapeutics
https://www.readbyqxmd.com/read/27912033/human-factor-considerations-for-artificial-pancreas-research
#3
Linda A Gonder-Frederick, Jesse H Grabman, Jaclyn A Shepard
No abstract text is available yet for this article.
December 2, 2016: Diabetes Technology & Therapeutics
https://www.readbyqxmd.com/read/27835049/insulin-pump-failures-has-there-been-an-improvement-update-of-a-prospective-observational-study
#4
Agathe Guenego, Guillaume Bouzillé, Stéphanie Breitel, Annabelle Esvant, Jean-Yves Poirier, Fabrice Bonnet, Isabelle Guilhem
BACKGROUND: Insulin pump failures had been assessed in our center by a prospective observational study from 2001 to 2007. The aim of this study was to update our data since 2008 and to determine whether there exist specific risk factors for insulin pump failures. METHODS: All insulin pump defects were prospectively collected between 2008 and 2013 in a monocentric cohort of 350 new pumps. Clinical consequences were recorded. Brand and model of pumps and type of defects and patients' characteristics (gender, type of diabetes, age at diabetes diagnosis, age at first pump, pump treatment duration, number of previous pumps, and number of previous pump failures) were tested for possible association with insulin pump failure...
November 11, 2016: Diabetes Technology & Therapeutics
https://www.readbyqxmd.com/read/27835045/cardiovascular-outcomes-of-new-medications-for-type-2-diabetes
#5
Jennifer M Trujillo, Sara A Wettergreen, Wesley A Nuffer, Samuel L Ellis, Michael T McDermott
Cardiovascular (CV) disease remains the leading cause of death in people with diabetes, highlighting the importance of using treatment options that do not increase CV risk or possibly decrease CV outcomes. Since 2008, the Food and Drug Administration has required demonstration of CV safety for all new medications developed for the glycemic management of diabetes. Seven trials have been published that have established CV safety for three DPP-4 inhibitors (alogliptin, saxagliptin, and sitagliptin), three GLP-1 receptor agonists (liraglutide, lixisenatide, and semaglutide), and one sodium-glucose cotransporter-2 inhibitor (empagliflozin)...
November 11, 2016: Diabetes Technology & Therapeutics
https://www.readbyqxmd.com/read/27835037/glycemia-treatment-satisfaction-cognition-and-sleep-quality-in-adults-and-adolescents-with-type-1-diabetes-when-using-a-closed-loop-system-overnight-versus-sensor-augmented-pump-with-low-glucose-suspend-function-a-randomized-crossover-study
#6
Amin Sharifi, Martin I De Bock, Dilshani Jayawardene, Margaret M Loh, Jodie C Horsburgh, Carolyn L Berthold, Nirubasini Paramalingam, Leon A Bach, Peter G Colman, Elizabeth A Davis, Benyamin Grosman, Christel Hendrieckx, Alicia J Jenkins, Kavita Kumareswaran, Natalie Kurtz, Andrew Kyoong, Richard J MacIsaac, Jane Speight, Steven Trawley, Glenn M Ward, Anirban Roy, Timothy W Jones, David N O'Neal
BACKGROUND: We compared glycemia, treatment satisfaction, sleep quality, and cognition using a nighttime Android-based hybrid closed-loop system (Android-HCLS) with sensor-augmented pump with low-glucose suspend function (SAP-LGS) in people with type 1 diabetes. MATERIALS AND METHODS: An open-label, prospective, randomized crossover study of 16 adults (mean [SD] age 42.1 [9.6] years) and 12 adolescents (15.2 [1.6] years) was conducted. All participants completed four consecutive nights at home with Android-HCLS (proportional integral derivative with insulin feedback algorithm; Medtronic) and SAP-LGS...
November 11, 2016: Diabetes Technology & Therapeutics
https://www.readbyqxmd.com/read/27788032/the-use-of-mobile-applications-among-adolescents-with-type-1-diabetes-results-from-diabetes-miles-youth-australia
#7
Steven Trawley, Jessica L Browne, Virginia L Hagger, Christel Hendrieckx, Elizabeth Holmes-Truscott, Frans Pouwer, Timothy C Skinner, Jane Speight
BACKGROUND: The use of mobile applications ("apps") for diabetes management is a rapidly developing area and has relevance to adolescents who tend to be early technology adopters. Apps may be useful for supporting self-management or connecting young people with type 1 diabetes (T1D) with their peers. However, outside controlled trials testing the effectiveness of apps, little is known about app usage in this population. Our aim was to explore app usage among adolescents with T1D. METHODS: Diabetes MILES Youth-Australia is a national, online cross-sectional survey focused on behavioral and psychosocial aspects relevant to adolescents with T1D...
October 27, 2016: Diabetes Technology & Therapeutics
https://www.readbyqxmd.com/read/27704875/physiology-invariant-meal-detection-for-type-1-diabetes
#8
James Weimer, Sanjian Chen, Amy Peleckis, Michael R Rickels, Insup Lee
BACKGROUND: Fully automated artificial pancreas systems require meal detectors to supplement blood glucose level regulation, where false meal detections can cause unnecessary insulin delivery with potentially fatal consequences, and missed detections may cause the patient to experience extreme hyperglycemia. Most existing meal detectors monitor various measures of glucose rate-of-change to detect meals where varying physiology and meal content complicate balancing detector sensitivity versus specificity...
October 5, 2016: Diabetes Technology & Therapeutics
https://www.readbyqxmd.com/read/27860501/should-glp-1-receptor-agonists-be-the-first-line-of-treatment-for-type-2-diabetes
#9
Richard E Pratley
No abstract text is available yet for this article.
November 2016: Diabetes Technology & Therapeutics
https://www.readbyqxmd.com/read/27860500/correction-to-diabetes-technol-ther-2016-18-10-610-615
#10
(no author information available yet)
No abstract text is available yet for this article.
November 2016: Diabetes Technology & Therapeutics
https://www.readbyqxmd.com/read/27860499/premixed-insulin-analogue-compared-with-basal-plus-regimen-for-inpatient-glycemic-control
#11
Abraham Edgar Gracia-Ramos, María Del Pilar Cruz-Domínguez, Eduardo Osiris Madrigal-Santillán, José Antonio Morales-González, Eduardo Madrigal-Bujaidar, José Leopoldo Aguilar-Faisal
BACKGROUND: No previous studies have investigated the use of a premixed insulin analogue in a hospital setting. OBJECTIVE: To compare the efficacy and safety of treatment with premixed insulin analogue (insulin lispro mix 75/25, LM75/25) with the basal-plus regimen with insulin glargine in hospitalized patients with type 2 diabetes (T2D). MATERIALS AND METHODS: A randomized clinical trial in hospitalized patients with T2D and glucose >140 mg/dL on admission was performed...
November 2016: Diabetes Technology & Therapeutics
https://www.readbyqxmd.com/read/27860498/clinical-outcomes-after-1-year-of-augmented-insulin-pump-therapy-in-patients-with-diabetes-in-a-specialized-diabetes-center-in-medell%C3%A3-n-colombia
#12
Alex Ramirez-Rincon, Jaime Hincapie-García, Claudia Monsalve Arango, Natalia Aristizabal, Estefany Castillo, Gloria Hincapie, Eliana Zapata, Diana Paola Cuesta, Maria Delgado, Veronica Abad, Jose Luis Torres, Andres Palacio, José Fernando Botero
BACKGROUND: Type 1 diabetes can be difficult to control. Augmented pump therapy (CSII-rtCGM) has become an important tool for controlling blood glucose and decreasing hypoglycemia. METHODS: Describe the results 1 year after starting CSII-rtCGM in patients with diabetes in Medellín, Colombia. This is an observational, retrospective study. Patients with type 1 and type 2 diabetes started on CSII-rtCGM between January 2008 and June 2015 were included. Qualitative variables were analyzed as absolute or relative frequencies...
November 2016: Diabetes Technology & Therapeutics
https://www.readbyqxmd.com/read/27860497/high-throughput-screening-in-general-population-for-type-1-diabetes
#13
Zhiyuan Zhao, Liping Yu
No abstract text is available yet for this article.
November 2016: Diabetes Technology & Therapeutics
https://www.readbyqxmd.com/read/27860496/predicting-insulin-treatment-scenarios-with-the-net-effect-method-domain-of-validity
#14
Martina Vettoretti, Andrea Facchinetti, Giovanni Sparacino, Claudio Cobelli
BACKGROUND: A simulation methodology based on the net effect, a signal estimated from continuous glucose monitoring (CGM) and insulin data accounting for sources of glucose variability, for example, meals and exercise, has been proposed. This method has been recently used to "replay" real-life treatment scenarios and determine the minimal level of CGM sensor accuracy required for nonadjunctive use. Given the potential of the net effect method, it is important to assess its domain of validity...
November 2016: Diabetes Technology & Therapeutics
https://www.readbyqxmd.com/read/27753510/pok%C3%A3-mon-go-obesity-and-diabetes-a-perspective-from-india
#15
Amerta Ghosh, Anoop Misra
No abstract text is available yet for this article.
November 2016: Diabetes Technology & Therapeutics
https://www.readbyqxmd.com/read/27728773/study-of-glycemic-variability-through-time-series-analyses-detrended-fluctuation-analysis-and-poincar%C3%A3-plot-in-children-and-adolescents-with-type-1-diabetes
#16
Leonor García Maset, Lidia Blasco González, Gonzalo Llop Furquet, Francisco Montes Suay, Roberto Hernández Marco
BACKGROUND: Time series analysis provides information on blood glucose dynamics that is unattainable with conventional glycemic variability (GV) indices. To date, no studies have been published on these parameters in pediatric patients with type 1 diabetes. Our aim is to evaluate the relationship between time series analysis and conventional GV indices, and glycosylated hemoglobin (HbA1c) levels. METHODS: This is a transversal study of 41 children and adolescents with type 1 diabetes...
November 2016: Diabetes Technology & Therapeutics
https://www.readbyqxmd.com/read/27710038/9th-annual-symposium-on-self-monitoring-of-blood-glucose-april-28-30-2016-madrid-spain
#17
Christopher G Parkin, Anita Homberg, Rolf Hinzmann
International experts in the field of diabetes and diabetes technology met in Madrid, Spain, for the 9th Annual Symposium on Self-Monitoring of Blood Glucose. The goal of these meetings is to establish a global network of experts, thus facilitating new collaborations and research projects to improve the lives of people with diabetes. The 2016 meeting comprised a comprehensive scientific program, parallel interactive workshops, and two keynote lectures.
November 2016: Diabetes Technology & Therapeutics
https://www.readbyqxmd.com/read/27552135/3-screen-elisa-for-high-throughput-detection-of-beta-cell-autoantibodies-in-capillary-blood
#18
Anette-G Ziegler, Florian Haupt, Marlon Scholz, Katharina Weininger, Susanne Wittich, Stephanie Löbner, Claudia Matzke, Cigdem Gezginci, Stephanie Riethausen, Andreas Beyerlein, Stephanie Zillmer, Marie Amoroso, Rebecca Coles, Michael Powell, Jadwiga Furmaniak, Bernard Rees Smith, Christiane Winkler, Ezio Bonifacio, Peter Achenbach
BACKGROUND: Testing for beta cell autoantibodies is used for wide-scale identification of early stages of type 1 diabetes. This requires suitable screening assays. We aimed to establish screening that utilized a first step assay (3 Screen) able to detect autoantibodies to the target antigens glutamic acid decarboxylase-65 (GAD), insulinoma-associated antigen 2 (IA-2), and zinc transporter 8 (ZnT8) to identify children positive for multiple beta cell autoantibodies. METHODS: An ELISA format was used where plates were coated with a mixture of recombinant GAD, IA-2, and ZnT8325W/R-dimer molecules...
November 2016: Diabetes Technology & Therapeutics
https://www.readbyqxmd.com/read/27525540/efficacy-and-tolerability-of-exenatide-once-weekly-over-6-years-in-patients-with-type-2-diabetes-an-uncontrolled-open-label-extension-of-the-duration-1-study
#19
Robert R Henry, Eric J Klein, Jenny Han, Nayyar Iqbal
BACKGROUND: Long-term treatment is necessary to slow the progression of type 2 diabetes (T2D). Here, we examined the safety and efficacy of 6 years of treatment with exenatide once weekly (QW) among patients with T2D in the DURATION-1 trial. METHODS: The study enrolled patients aged ≥16 years with T2D treated primarily with metformin and sulfonylureas. Following 30 weeks of randomized treatment with exenatide QW 2 mg or exenatide twice daily 10 μg, patients entered an uncontrolled, open-label, open-ended study phase in which all patients received exenatide QW 2 mg...
November 2016: Diabetes Technology & Therapeutics
https://www.readbyqxmd.com/read/27749115/web-based-management-trial-of-diabetes-care
#20
Katharine D Barnard, Amanda Blatch-Jones
No abstract text is available yet for this article.
October 2016: Diabetes Technology & Therapeutics
journal
journal
34712
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"